Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTQ5082 Phase 1 in Healthy Volunteers
NCT06560593Phase 1Not yet recruiting
- Sponsor
- Nanjing Chia-Tai Tianqing Pharmaceutical
- Start
- Aug 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NTQ5082 in Complement-dependent hemolytic anemia (CDHA) and paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Nanjing Chia-Tai Tianqing Pharmaceutical. Primary endpoint: Safety and tolerability up to 21 days. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
NTQ5082
03
Conditions
Complement-dependent hemolytic anemia (CDHA)paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT06560593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06560593.